PetMed Express (NASDAQ:PETS) Releases Quarterly Earnings Results, Misses Estimates By $0.01 EPS

PetMed Express (NASDAQ:PETS) issued its quarterly earnings data on Tuesday. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.01), FiscalAI reports. The company had revenue of $42.82 million for the quarter, compared to the consensus estimate of $52.00 million. PetMed Express had a negative return on equity of 70.74% and a negative net margin of 32.00%.During the same period in the prior year, the company earned ($0.56) EPS.

Here are the key takeaways from PetMed Express’ conference call:

• PetMed Express said fiscal 2026 was a “pivotal year” focused on stabilizing the business, improving internal controls, and restoring regulatory compliance, including filing delayed reports and remediating three previously disclosed material weaknesses.
• Revenue declines slowed in the second half, and Q4 net sales rose sequentially versus Q3 for the first time in a fourth quarter since fiscal 2024, with management citing early traction in prescription meds, food sales, and autoship signups.
• Full-year sales fell 21.1% to $179 million, while Q4 revenue declined 15.6% year over year, showing the company is still dealing with substantial top-line pressure.
• Management highlighted meaningful cost actions, including exiting underperforming vendor relationships that should generate about $6.1 million in annualized savings, along with lower G&A from broader optimization efforts.
• The company ended the year with $21.4 million in cash and no debt, but full-year adjusted EBITDA was negative $15.4 million and net loss widened significantly due to goodwill impairment, inventory write-downs, and legal/severance costs.

PetMed Express Stock Performance

PetMed Express stock opened at $1.78 on Thursday. PetMed Express has a 52 week low of $1.57 and a 52 week high of $4.32. The stock has a market capitalization of $38.09 million, a P/E ratio of -0.65 and a beta of 0.77. The stock has a fifty day moving average of $2.26 and a 200-day moving average of $2.61.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on PETS shares. Weiss Ratings reissued a “sell (d-)” rating on shares of PetMed Express in a research report on Tuesday, May 12th. Zacks Research raised PetMed Express to a “hold” rating in a research report on Thursday, April 30th. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Reduce”.

Hedge Funds Weigh In On PetMed Express

A number of institutional investors have recently modified their holdings of the business. Occudo Quantitative Strategies LP acquired a new position in PetMed Express in the 2nd quarter worth about $51,000. Oxford Asset Management LLP acquired a new position in PetMed Express in the 2nd quarter worth about $55,000. CIBC Private Wealth Group LLC acquired a new position in PetMed Express in the 3rd quarter worth about $75,000. Jain Global LLC acquired a new position in PetMed Express in the 4th quarter worth about $78,000. Finally, Bridgeway Capital Management LLC increased its holdings in PetMed Express by 96.2% in the 2nd quarter. Bridgeway Capital Management LLC now owns 40,800 shares of the company’s stock worth $135,000 after purchasing an additional 20,000 shares in the last quarter. Institutional investors and hedge funds own 73.33% of the company’s stock.

PetMed Express Company Profile

PetMed Express, Inc operates as an online and catalog-based pet pharmacy and retail supplier under the 1-800-PetMeds brand name. The company distributes prescription and non‐prescription medications, nutritional supplements, flea and tick control products, and a range of pet health supplies directly to consumers. Through its licensed veterinary pharmacy in Delray Beach, Florida, PetMed Express fills orders for dogs, cats and other companion animals, offering both branded and generic products alongside its own private‐label formulations.

Founded in 1996 by Marc Puleo, PetMed Express built its business on the premise of convenience and cost savings for pet owners seeking reliable access to veterinary medications.